On the Effects of Misclassification in Estimating Efficacy With Application to Recent COVID-19 Vaccine Trials
Buonaccorsi, J. P.
Show abstract
The recent trials for proposed COVID-19 vaccines have garnered a considerable amount of attention and as of this writing extensive vaccination efforts are underway. The first two vaccines approved in the United States are the Moderna and Pfizer vaccines both with estimated efficacy near 95%. One question which has received limited attention, and which we address here, is what affect false positives or false negatives have on the estimated efficacy. Expressions for potential bias due to misclassification of COVID status are developed as are general formulas to adjust for misclassification, allowing for either differential or non-differential misclassification. These results are illustrated with numerical investigations pertinent to the Moderna and Pfizer trials. The general conclusion, fortunately, is that the potential misclassification of COVID status almost always would lead to underestimation of the efficacy and that correcting for false positives or negatives will typically lead to even higher estimated efficacy.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Estimation of Vaccine Efficacy for Variants that Emerge After the Placebo Group Is Vaccinated 97%
- A Double Machine Learning Approach for the Evaluation of COVID-19 Vaccine Effectiveness under the Test-Negative Design: Analysis of Québec Administrative Data 94%
- HIV Estimation Using Population-Based Surveys With Non-Response: A Partial Identification Approach * 94%
Similar papers in this journal
- Evaluating the effects of vaccine rollout policies in European countries: A simulation study 94%
- Estimating the impact of interventions against COVID-19: from lockdown to vaccination 93%
- SARS-CoV-2 infection dynamics in Denmark, February through October 2020: Nature of the past epidemic and how it may develop in the future 93%
Similar papers in this journal
Similar papers in this journal
- Causal Estimands for Infectious Disease Count Outcomes to Investigate the Public Health Impact of Interventions 94%
- Incorporating efficacy data from initial trials into subsequent evaluations of vaccines against respiratory syncytial virus 94%
- Use of recently vaccinated individuals to detect bias in test-negative case-control studies of COVID-19 vaccine effectiveness 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.